Not a licensed clinician? No worries! Bring cardiometabolic intelligence to your practice at CMiQCoach.com.
Visit CMiQCoach.com →Most labs miss true hepatic dysfunction — the upstream driver of cardiometabolic risk. CMiQHealth is the only clinical system built to find it, assess the full cardiometabolic picture, and give you a structured path to reverse it.
The Implementation Guide is curated for licensed clinicians. You'll hear from us personally.
Testing infrastructure, report architecture, clinical workflow, DBS logistics, and practice differentiation — all in one document.
For licensed clinicians only. We review each request and send the guide directly. Your information is never shared.
Not a licensed clinician? No worries! Bring cardiometabolic intelligence to your practice at CMiQCoach.com.
We'll review your credentials and send the Implementation Guide to your practice email. Expect to hear from us within one business day.
MASLD affects 1 in 3 adults and drives insulin resistance, cardiovascular risk, and systemic inflammation. No major practitioner-facing panel quantifies liver strain — until now.
Reference ranges tell patients whether a number is statistically normal. They don't translate it into actionable risk context or a clinical narrative your patient can act on.
Only 6.8% of American adults meet all five criteria for ideal cardiometabolic health. The majority are walking in your door with unquantified risk and no roadmap. (O'Hearn et al., JACC 2022)
Isolated values don't capture the integrated physiologic strain driving cardiometabolic disease. Risk lives in the interaction between domains, not individual data points.
Even clinicians who understand cardiometabolic medicine lack a complete testing, reporting, and patient engagement system built for their workflow.
CMiQHealth uses many of the same biomarkers your patients already have on file. What's different is everything done with them.
| Feature | Standard Blood Lab | CMiQHealth |
|---|---|---|
| Risk Scoring How marker values communicate health risk | Raw value flagged as normal or abnormal against a population reference range | Every marker transformed into a 0–10 iQ strain score calibrated to dose-response outcome data |
| Optimal vs. Standard Range Range precision for clinical interpretation | One reference range — typically population average, not optimal | Both optimal and standard ranges reported for every marker, giving practitioners a higher-resolution target |
| Fatty Liver Index (FLI) Validated hepatic steatosis surrogate | Not reported | Featured standalone dial with iQ score — the only practitioner-facing panel reporting FLI in an integrated cardiometabolic context |
| Body Composition Integration Anthropometric markers in clinical context | Not reported — height, weight, waist circumference excluded from standard lab panels | BMI, waist circumference, waist-to-height ratio, and TyG-WHtR integrated into CAMD domain scoring and FLI calculation |
| Atherogenic Markers Advanced cardiovascular risk indicators | Standard lipid panel only — LDL, HDL, Total Cholesterol, Triglycerides | ApoB, Remnant Cholesterol, Atherogenic Index of Plasma, and Lp(a) reported as contextual risk markers within the HVHD domain |
| Composite Domain Scores Integrated multi-marker physiologic picture | Not reported — markers presented as isolated individual values with no integration | Five domain scores (LMDD, GIRD, HVHD, IOSD, CAMD) composite related markers into a single physiologic strain picture per domain |
| Single Composite Index Total cardiometabolic strain in one number | Not reported | The CMiQ Index aggregates all five domain scores into a single 0–10 measure of total cardiometabolic strain |
| Explanatory Illustration Visual patient education on systemic disease pathways | Not included | Full-page illustrated cascade diagram showing how liver dysfunction drives cardiovascular, glycemic, and inflammatory disease — designed for the patient conversation |
| Actionable Recommendations Clinical guidance derived from results | Not included — values reported without clinical interpretation or next-step guidance | Domain-specific recommendations with strain-calibrated clinical guidance and retest intervals generated automatically for every report |
| Patient-Ready Narrative Report designed for the patient conversation | Lab printout with values and flags — requires practitioner translation before patient can understand it | Structured patient education document with plain-language domain explanations, illustrations, and personalized recommendations built in |
The Physiologic Strain Model (PSM) converts raw biomarkers into calibrated iQ scores across five integrated domains, composited into a single CMiQ Index. Every score is anchored to dose-response outcome data from peer-reviewed prospective cohort research.
FLI is a validated composite index derived from BMI, waist circumference, triglycerides, and GGT — the most extensively validated non-invasive surrogate for hepatic steatosis in population research. To our knowledge, no other practitioner-facing panel reports it in an integrated cardiometabolic context. It is the entry point to a comprehensive picture of cardiovascular strain, glycemic dysregulation, systemic inflammation, and adiposity-driven metabolic load.
The flagship panel. Covers liver, glycemic, cardiovascular, inflammatory, and adiposity domains with FLI as a featured standalone dial. Includes ApoB, Lp(a), and full domain scoring.
Expands the CMiQ panel with advanced thyroid evaluation interpreted through a metabolic lens — including identification of MASCH, an original CMiQHealth clinical concept addressing thyroid-metabolic interaction in patients with normal TSH.
The most comprehensive panel. Designed for multi-system metabolic complexity — covers the full endocrine-metabolic-thyroid axis in a unified clinical context.
CMiQ reports are built on an evidence architecture that, to our knowledge, has no equivalent in practitioner-facing testing: every marker and index is anchored to dose-response outcome data from peer-reviewed prospective cohorts representing more than 70 million participants.
Every CMiQ biomarker and index has an individual dose-response risk curve and peer-reviewed evidence report. PSM Evidence Rigor Scorecard available upon request.
No other practitioner-facing platform integrates FLI into a validated cardiometabolic panel. CMiQCertified practitioners occupy a credentialed position in a category that doesn't exist elsewhere.
1 in 3 patients has MASLD. 93% have suboptimal cardiometabolic health. CMiQHealth gives you the tools to find them, quantify their risk, and guide them toward reversal.
The MLR-90 protocol is a turnkey patient engagement system — materials, tracking tools, and facilitation guides — deployed as your own program. No subscription. No minimum volume.
70+ million participants across peer-reviewed prospective cohorts. When a patient or colleague asks why you're using this panel, the answer is unambiguous.
"Everybody's talking about cardiometabolic health. Nobody's talking about the liver."
CMiQ reports are built on an evidence architecture that, to our knowledge, has no equivalent in practitioner-facing testing: every marker and index is anchored to dose-response outcome data from peer-reviewed prospective cohorts representing more than 70 million participants.
CMiQHealth Competitive Positioning